Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7621733 | 0.86 | MAOB (0.45) | MAOBMAOAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL30715525 | 0.77 | MAOB (0.45) | MAOBMAOAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL2821725 | 0.77 | KDM1A (0.47) | MAOBMAOAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL2824969 | 0.77 | KDM1A (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL23383992 | 0.77 | MAOB (0.49) | MAOBMAOAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL23490000 | 0.77 | MAOB (0.45) | MAOBMAOAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8782162 | 0.77 | MAOB (0.45) | MAOBMAOAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL14870555 | 0.77 | MAOB (0.49) | MAOBMAOAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL6667045 | 0.77 | IDO1 (0.47) | MAOBMAOAHTR2ASIGMAR1 | |
| SCHEMBL2824963 | 0.77 | KDM1A (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070281-A | Novel compounds as sodium channel modulators and uses thereof | 英矽智能科技(上海)有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
| CN-1717467-A | Indane compound-containing nematic liquid crystal composition | DAINIPPON INK & CHEMICALS (JP) | 2006-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | CFTR, AADAT, FANCI | MAOB 669/4885MAOA 760/4885GRIN2D 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.